Literature DB >> 30227250

Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis.

Linyan Chen1, Yi Zhang1, Yuan Cheng1, Dan Zhang1, Sha Zhu1, Xuelei Ma2.   

Abstract

Because of the deep research about tumorigenesis mechanism, the cognition of cancer has been transferred to molecular level from morphology. Previous articles reported a potential connection between circulating cell-free DNA (cfDNA) and prognosis of pancreatic cancer. A total of 18 related articles including 1243 patients were enrolled to access the relationship between cfDNA and prognosis of pancreatic cancer. The hazard ratio (HR) was used to combine the univariate and multivariate results of included studies. Our result performed that the cfDNA had significant prognostic value in predicting OS (HR = 2.41, 95%CI: 1.93-3.02, I2 = 60%) and PFS (HR = 2.47, 95%CI: 1.80-3.40, I2 = 0%) in univariate analysis. The multivariate analyses about OS (HR = 2.57, 95%CI: 1.95-3.38, I2 = 66%) and PFS (HR = 2.31, 95%CI: 1.47-3.64, I2 = 0%) also showed significance. In conclusion, the cfDNA was a significant prognostic factor for OS and PFS in patients with pancreatic cancer. The mutation (Kras, ERBB2-exon17 and KrasG12V), circulating tumor DNA (ctDNA) presence, hypermethylation and higher concentration of cfDNA were both associated with worse survival results in pancreatic cancer.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Circulating cell-free DNA; Meta-analysis; Pancreatic cancer; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30227250     DOI: 10.1016/j.gene.2018.09.029

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  15 in total

Review 1.  Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging.

Authors:  Ajaykumar C Morani; Abdelrahman K Hanafy; Nisha S Ramani; Venkata S Katabathina; Sireesha Yedururi; Anil K Dasyam; Srinivasa R Prasad
Journal:  Radiol Imaging Cancer       Date:  2020-03-13

2.  Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.

Authors:  William J Chapin; Jacob E Till; Wei-Ting Hwang; Jennifer R Eads; Thomas B Karasic; Peter J O'Dwyer; Charles J Schneider; Ursina R Teitelbaum; Janae Romeo; Taylor A Black; Theresa E Christensen; Colleen Redlinger Tabery; Amanda Anderson; Megan Slade; Michael LaRiviere; Stephanie S Yee; Kim A Reiss; Mark H O'Hara; Erica L Carpenter
Journal:  JCO Precis Oncol       Date:  2022-07

3.  New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020.

Authors:  Muhammad Wasif Saif
Journal:  JOP       Date:  2020-08

4.  Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.

Authors:  Yasunori Uesato; Naoki Sasahira; Masato Ozaka; Takashi Sasaki; Mitsuhisa Takatsuki; Hitoshi Zembutsu
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

5.  Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.

Authors:  Sandra Liebs; Ulrich Keilholz; Inge Kehler; Caroline Schweiger; Johannes Haybäck; Anika Nonnenmacher
Journal:  Cancer Med       Date:  2019-05-27       Impact factor: 4.452

Review 6.  Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers.

Authors:  Richard A Jacobson; Emily Munding; Dana M Hayden; Mia Levy; Timothy M Kuzel; Sam G Pappas; Ashiq Masood
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639

Review 7.  Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma.

Authors:  Matthew Loft; Belinda Lee; Jeanne Tie; Peter Gibbs
Journal:  J Pers Med       Date:  2019-07-18

8.  Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.

Authors:  He Cheng; Guopei Luo; Kaizhou Jin; Zhiyao Fan; Qiuyi Huang; Yitao Gong; Jin Xu; Xianjun Yu; Chen Liu
Journal:  Cancer Med       Date:  2020-02-03       Impact factor: 4.452

9.  Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.

Authors:  Marin Strijker; Eline C Soer; Matteo de Pastena; Aafke Creemers; Alberto Balduzzi; Jamie J Beagan; Olivier R Busch; Otto M van Delden; Hans Halfwerk; Jeanin E van Hooft; Krijn P van Lienden; Giovanni Marchegiani; Sybren L Meijer; Carel J van Noesel; Roy J Reinten; Eva Roos; Sandor Schokker; Joanne Verheij; Marc J van de Vijver; Cynthia Waasdorp; Johanna W Wilmink; Bauke Ylstra; Marc G Besselink; Maarten F Bijlsma; Frederike Dijk; Hanneke W van Laarhoven
Journal:  Int J Cancer       Date:  2019-08-13       Impact factor: 7.396

10.  Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.

Authors:  Fumiaki Watanabe; Koichi Suzuki; Sawako Tamaki; Iku Abe; Yuhei Endo; Yuji Takayama; Hideki Ishikawa; Nao Kakizawa; Masaaki Saito; Kazushige Futsuhara; Hiroshi Noda; Fumio Konishi; Toshiki Rikiyama
Journal:  PLoS One       Date:  2019-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.